This site is intended for healthcare professionals

SELECTION study on filgotinib in ulcerative colitis is published in The Lancet. Galapagos NV.

Read time: 1 mins
Last updated:7th Jun 2021
Published:5th Jun 2021
Galapagos NV announced that primary and secondary endpoint results from the phase III SELECTION induction and maintenance study (NCT02914522) were published in The Lancet. The study, sponsored by Gilead Sciences, Inc., was designed to assess the efficacy and safety of the once-daily, oral preferential JAK1 inhibitor, filgotinib, under investigation in patients with moderately to severely active ulcerative colitis (UC).
Condition: Ulcerative Colitis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest